The federal government’s supply of Covid-19 treatment remdesivir will run out by June 29, leaving hospitals worried about their supplies for the summer and fall.
The Department of Health and Human Services is “currently in conversations with Gilead Sciences, Inc. to determine how their anticipated inventory of 2 million doses by year’s end will be allocated and when,” a spokesperson told Bloomberg Law Thursday.
Remdesivir, orginally developed to treat Ebola, was one of the first drugs to get an emergency use authorization for Covid-19. The designation allows drugs to be used in ways not previously approved. The only other medicines ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.